227 related articles for article (PubMed ID: 10482942)
1. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
4. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
[TBL] [Abstract][Full Text] [Related]
5. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
[TBL] [Abstract][Full Text] [Related]
7. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy.
Saito AM; Zahrieh D; Cutler C; Ho VT; Antin JH; Soiffer RJ; Alyea EP; Lee SJ
Bone Marrow Transplant; 2007 Aug; 40(3):209-17. PubMed ID: 17563734
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
9. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
10. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
[TBL] [Abstract][Full Text] [Related]
12. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
13. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: a single-center experience.
Takenaka K; Shinagawa K; Sunami K; Fujii N; Hiramatsu Y; Maeda Y; Nawa Y; Katayama Y; Teshima T; Ishimaru F; Kiura K; Ikeda K; Harada M
Int J Hematol; 2000 Oct; 72(3):362-70. PubMed ID: 11185996
[TBL] [Abstract][Full Text] [Related]
15. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
[TBL] [Abstract][Full Text] [Related]
16. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
Krejci M; Mayer J; Doubek M; Brychtova Y; Pospisil Z; Racil Z; Dvorakova D; Lengerova M; Horky O; Koristek Z; Dolezal T; Vorlicek J
Bone Marrow Transplant; 2006 Oct; 38(7):483-91. PubMed ID: 16980996
[TBL] [Abstract][Full Text] [Related]
18. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation.
Faucher C; Fortanier C; Viens P; Le Corroller AG; Chabannon C; Camerlo J; Novakovitch G; Gastaut JA; Maraninchi D; Moatti JP; Blaise D
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S92-8. PubMed ID: 9712506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
